Prelude Therapeutics, Inc. PRLD 深 滬
等待開盤 09-23 09:30:00 美东时间
4.85
+0.150
+3.19%
華盛通- 最 高4.91
- 今 開4.70
- 成交量 42.46万股
- 最 低 4.63
- 昨 收 4.70
- 總市值 3.87亿
- 52周最高 6.83
- 市盈率 靜 --
- 換手率 0.53%
- 52周最低 1.15
- 委 比 59.18%
- 總股本 7980.35万
- 歷史最高 95.375
- 量 比 0.83
- 振 幅 5.96%
- 歷史最低 0.6101
- 每 手 1
- 風險率 1.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Overweight rating and announces Price Target of $12.
09-17 20:07
Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. "Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with cu...
09-10 19:04
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Prelude Therapeutics announced FDA clearance for a Phase 1 study of PRT13722, an oral KAT6A selective degrader, for HR+/HER2- breast cancer. The trial, expected to begin enrolling patients in Q4 2026, will evaluate safety, tolerability, and antitumor activity as monotherapy and in combination with other therapies. PRT13722 aims to address limitations of dual KAT6A/B inhibitors by improving efficacy and hematological safety.
09-10 11:01
美股牛股 | 比特币突破7.7万美元大关！加密概念股普升，嘉楠科技劲升16%，MARA升逾15%，比特数字升近14%
政策利好集中释放！比特币突破7.5万美元大关，加密概念股普升，嘉楠科技劲升16%，MARA升逾15%，比特数字升近14%；ANDG升近12%，发售1.8亿美元股票>>
08-21 16:01
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-12 03:18
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 65.85 percent increase over losses of $(0.41) per share from the same period last year. The company reported $5.704 million in sales this qu...
08-11 19:23
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q2 2026 financial results with $155 million in cash and plans to initiate a Phase 1 study for its KAT6A degrader PRT13722 in HR+ breast cancer by Q4 2026. The company also continues enrollment in its Phase 1 study for PRT12396, a JAK2V617F inhibitor for PV and MF. Financials show a net loss of $13.9 million, down from $31.2 million in 2025, with R&D and G&A expenses decreasing. The company expects its cash runway to ...
08-11 11:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE:SHW) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 guidance. Sherwin-Williams reported quarterly earnings of ...
07-28 22:05
